Search for a trial

A Phase 2b, Randomized, Controlled Trial Evaluating GS 5806 in Lung Transplant (LT) Recipients with Respiratory Syncytial Virus (RSV) Infection

The primary objective of this study is as follows:* To evaluate the effect of presatovir (GS-5806) on nasal RSV viral load in RSV positive LT recipients with acute respiratory symptomsThe secondary objectives of this study are as follows: * To…

A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of
Inhaled JNJ-49095397 (RV568) in Subjects With Moderate to Severe Chronic Obstructive
Pulmonary Disease

Primary ObjectiveThe primary objective is to assess the efficacy (as measured by change from baseline in prebronchodilator [preBD] percent predicted forced expiratory volume in one second [FEV1]) of JNJ-49095397 compared with placebo in subjects…

Pharmacokinetic evaluation and tolerability of dry powder tobramycin by a novel device in patients with non cystic fibrosis bronchiectasis

The first objective to investigate is the pharmacokinetics of DP tobramycin using the Cyclops® at four different dosages. The other objective is the local tolerability of DP tobramycin using the Cyclops® at four different dosages.

Nebulising Amoxicillin-Clavulanic Acid in Patients with COPD (NACAP)

To investigate whether inhalation of nebulised amoxicillin clavulanic acid is effective in reaching amoxicillin sputum levels >= MIC 90 in patient with an exacerbation of COPD.

A randomized, double-blind, placebo controlled, parallel group, multi-centre, 2-week treatment study to evaluate the safety and efficacy of fluticasone furoate nasal spray (FFNS) 110 mcg, administered either once daily or twice daily, compared with placebo, as effective monotherapy in the treatment of uncomplicated acute rhinosinusitis (ARS) in adult and adolescent subjects 12 years of age and older.

The objective of this study is to evaluate the safety and efficacy of two doses of FFNS (110 mcg once daily and 110 mcg twice daily) compared to placebo as monotherapy in the treatment of adult and adolescent subjects 12 years of age and older with…

A multi-center, randomized, double-blind, placebo-controlled, parallel group, repeated-dose study to evaluate the efficacy, safety, tolerability and pharmacokinetics of three different dosing regimens of inhaled indacaterol maleate in patients with persistent asthma

The purpose of this study is to give more information about indacaterol in similar doses but given either once a day, twice a day, or once every other day to patients with persistent asthma.

Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of;Aztreonam 75 mg Powder and Solvent for Nebuliser;Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric;Patients with Cystic Fibrosis (CF) and New Onset Lower Respiratory;Tract Culture Positive for Pseudomonas aeruginosa (PA)

The purpose of this study is to evaluate whether aztreonam solution for inhalation (AZLI) is safe and effective for the treatment and complete eradication of a lung infection with PA (Pseudomonas aeruginosa) in patients with Cystic Fibrosis (CF) and…

A Randomized Open Label Study Comparing the Safety, Tolerability and Pharmacokinetics (PK) of Amantadine Hydrochloride and Ribavirin with Oseltamivir Phosphate (TCAD) Administered Orally Versus Oseltamivir alone Administered Orally to Influenza A Virus Infected Hospitalized Immunocompromised Patients

Primary: To determine the safety and tolerability of TCAD administered orally to immunocompromised patients diagnosed with influenza ASecondary: To assess the antiviral effect, the speed of symptom resolution, and the influenza complication rate of…

A prospective study to evaluate the safety and efficacy of AdvaCoat Mx sinus gel for treatment of chronic rhinosinusitis without nasal polyps.

The purpose of the first part of the study is the evaluation of the first 9 subjects that will be conducted to confirm the 1.5 mL AdvaCoat Mx treatment volume per side as the desired volume for the expanded portion of the study. The purpose of the…

A randomized, double-blind, placebo controlled, multicentre study to determine the effect of QVA149 on lungfunction in patients with Chronic Obstructive Pulmonary Disease (COPD).

The purpose of this study is to evaluate the effects of QVA149 300/50, a fixed dose combination of QAB149 300µg and NVA237 50µg, versus placebo and two doses of QAB149 300µg and 600µg, in terms of lung function in patients with moderate to severe…

Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients with Multi-Drug Resistant Tuberculosis after successful intensive-phase treatment.

Primary endpoint: Evaluation of the safety of the novel anti-TB vaccine RUTI® (25*g FCMtb) in patients with MDR-TB favourably responding to second-line, standard MDRTB treatment through clinical, microbiological, and radiological response criteria.…

A randomized, double-blind, placebo-controlled, multicenter study of ensovibep (MP0420) in ambulatory adult patients with symptomatic COVID-19

The study has the purpose and rationale to establish the antiviral efficacy of ensovibep against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans, identify the optimal dose, and demonstrate its clinical value for treating COVID…

RESPIRE - A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19

• To demonstrate the efficacy of ATR-002 versus placebo in addition to standard of care based on the clinical severity status in adult hospitalized patients with COVID-19• To show that ATR-002 in addition to standard of care shortens the time to…

A Phase II/III seamless, randomised, double-blind, placebo-controlled, parallel-group,
group-sequential study to evaluate efficacy, safety and tolerability of BI 767551 for the
treatment of symptomatic, non-hospitalized adults with mild to moderate COVID-19.

The overall objective of this trial is to evaluate the concept of pharmacological activity of BI 767551 in non-hospitalized patients with mild to moderate COVID-19 symptoms and to identify a potentially efficacious and safe dose regimen from Phase…

A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease (study 214094)

Primary:Compare the efficacy of single IV injection with otilimab 90 mg in adults with severe pulmonary COVID-19 related disease.Secondary:Other aspects of efficacy. Safety and tolerability.

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Clinical Outcomes, Antiviral Activity, Safety, Tolerability, Pharmacokinetics, and Pharmacokinetics/Pharmacodynamics of JNJ-53718678 in Adult and Adolescent Hematopoietic Stem Cell Transplant Recipients with Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

To evaluate the clinical outcomes, antiviral activity, safety, tolerability, PK, and PK/PD of JNJ 53718678 in adult (ie, adult cohort) and adolescent (ie, adolescent cohort) HSCT recipients with an RSV upper respiratory tract infection (URT)I.The…

A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomonas aeruginosa (PsA) Pulmonary Infection

Primary Objective:To evaluate the safety and tolerability of nebulized BX004-A in CF subjects with chronic PsA pulmonary infection.Exploratory Objective:To evaluate the effect of BX004-A on sputum PsA burden, lung function, frequency of APEs, and…

Amoxicillin-clavulanic acid Levels in Sputum After Nebulization in AECOPD (ALSAN)

In this study we want to show adequate sputum levels are obtained throughout the day after inhalation of nebulized amoxicillin clavulanic acid in hospitalized AECOPD patients.

Potential of FX06 to prevent disease progression in hospitalised nonintubated COVID-19 patients (Ixion)

The primary objective is to demonstrate a difference in the proportion of patients with progressed/worsened disease state in patients receiving FX06 compared to patients receiving placebo until day 28.Assessment and treatment comparison of the…

Effect of Iodine treatment in patiënts with COVID-19 disease.

Demonstrate that iodine treatment has a beneficial effect on the course of COVID-19 disease. Beneficial effect is defined as less critically relevant deterioration such as transfers from regular to intensive care units, fewer days of hospitalization…